OBJECTIVE: To prospectively describe patient-reported outcomes (PROs) after preoperative chemoradiotherapy (pCRT) for rectal cancer. BACKGROUND: Little evidence is available on PROs after pCRT for rectal cancer. PATIENTS AND METHODS: Patients with rectal cancer, candidates to receive pCRT, were enrolled in a multicenter prospective observational trial. Health-related quality of life was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and its colorectal cancer module (QLQ-CR38), and fecal incontinence and bowel function were evaluated using the fecal incontinence score questionnaire and a set of ad hoc questions. Questionnaires were filled out before CRT (t₀), 2 to 3 weeks after completion of CRT (t₁), and at 6 (t₂) and 12 months (t₃) after surgery. Primary analysis of selected scales included: global quality of life, physical functioning, social functioning, fatigue, body image, future prospective, and gender-related sexual problems. RESULTS: Of 149 eligible patients, questionnaires were completed in 100%, 95%, 88% and 77% of cases at t0, t₁, t₂, and t₃, respectively. At t₃, 78% of patients reported stool fractionation and 72% sensation of incomplete defecation. Only 14% of patients had optimal continence. Physical/social functioning, fatigue, and body image showed a decrease just after pCRT and returned to baseline levels at 1 year after treatment. Global quality of life was stable over time. Male sexual problems were greatly impaired throughout the study period (P < 0.001) with major clinically meaningful changes between baseline and 1 year after treatment. CONCLUSIONS: These findings add to the body of evidence available regarding pCRT and help clinicians to make more informed treatment decisions.
OBJECTIVE: To prospectively describe patient-reported outcomes (PROs) after preoperative chemoradiotherapy (pCRT) for rectal cancer. BACKGROUND: Little evidence is available on PROs after pCRT for rectal cancer. PATIENTS AND METHODS: Patients with rectal cancer, candidates to receive pCRT, were enrolled in a multicenter prospective observational trial. Health-related quality of life was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and its colorectal cancer module (QLQ-CR38), and fecal incontinence and bowel function were evaluated using the fecal incontinence score questionnaire and a set of ad hoc questions. Questionnaires were filled out before CRT (t₀), 2 to 3 weeks after completion of CRT (t₁), and at 6 (t₂) and 12 months (t₃) after surgery. Primary analysis of selected scales included: global quality of life, physical functioning, social functioning, fatigue, body image, future prospective, and gender-related sexual problems. RESULTS: Of 149 eligible patients, questionnaires were completed in 100%, 95%, 88% and 77% of cases at t0, t₁, t₂, and t₃, respectively. At t₃, 78% of patients reported stool fractionation and 72% sensation of incomplete defecation. Only 14% of patients had optimal continence. Physical/social functioning, fatigue, and body image showed a decrease just after pCRT and returned to baseline levels at 1 year after treatment. Global quality of life was stable over time. Male sexual problems were greatly impaired throughout the study period (P < 0.001) with major clinically meaningful changes between baseline and 1 year after treatment. CONCLUSIONS: These findings add to the body of evidence available regarding pCRT and help clinicians to make more informed treatment decisions.
Authors: A Barina; A De Paoli; P Delrio; M Guerrieri; A Muratore; F Bianco; D Vespa; C Asteria; E Morpurgo; A Restivo; C Coco; U Pace; C Belluco; C Aschele; S Lonardi; V Valentini; G Mantello; I Maretto; P Del Bianco; A Perin; S Pucciarelli Journal: Tech Coloproctol Date: 2017-07-28 Impact factor: 3.781
Authors: Marcia M Russell; Patricia A Ganz; Samia Lopa; Greg Yothers; Clifford Y Ko; Amit Arora; James N Atkins; Nathan Bahary; Gamini S Soori; John M Robertson; Janice Eakle; Benjamin T Marchello; Timothy F Wozniak; Robert W Beart; Norman Wolmark Journal: Ann Surg Date: 2015-01 Impact factor: 12.969
Authors: M Bushati; S Pucciarelli; N Gennaro; I Maretto; P Toppan; A Perin; E D L Urso; A Bagatella; G Spolverato Journal: Int J Colorectal Dis Date: 2019-11-14 Impact factor: 2.571
Authors: Melissa S Y Thong; Floortje Mols; Xin S Wang; Valery E P P Lemmens; Tineke J Smilde; Lonneke V van de Poll-Franse Journal: Eur J Cancer Date: 2013-03-01 Impact factor: 9.162
Authors: Libertad T Flores; Antonia V Bennett; Ethel B Law; Carla Hajj; Mindy P Griffith; Karyn A Goodman Journal: Gastrointest Cancer Res Date: 2012-07